He says there has been an upswing in investors looking at companies. Plus, his thoughts on BioInvent, Oculis, and Camurus. Brought to you by

She discusses building systems around early diagnostics and treatment, rare disease discovery, mitochondrial disease and the brain,...

Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as...

Cait Brumme highlights MassChallenge's equity-free model and how it helps biotech entrepreneurs from the earliest stages to understanding...

Having been involved with Reata, Taysha Gene Therapies (founder), ReCode Therapeutics and more, RA has a good handle on the biotech scene...

Nicole Small discusses events that have recently taken place like the acquisition of Reata, ARPA-H choosing Dallas for a regional center,...

Dr. Scherer describes the work he is doing in areas like diabetes and fibro-inflammation. Plus, PriveBio's programs focusing on...

Biren Amin joins BiotechTV from the NYSE and discusses BridgeBio, Ocular Therapeutix, Apellis, Sarepta, Solid Bio, Cargo Therapeutics,...

Medical Director Fabrizio Calisti describes the fund, its foundation in the CNS but broad interest today, current portfolio holdings, and...

Managing Director Marco Baccanti explains how the foundation was created last year to boost the amount of IP and licensing that is...

Anders Bue Klein describes how the BI has made it easier for founders like him to take work from university and turn it into a company....

The former CEO of Prosensa and current contributor to numerous boards highlights the past and current successes that have made this region a

He shares his take on biotech and discusses Terns, Novo Nordisk, Corbus, Harmony Bio, IDEAYA, and Adverum.

He describes how Vedanta is isolating specific bacterial strains and using them as a defined composition for its medicines, and why he...

The VP of Lab Technologies at Aera Therapeutics describes what lab work was like before technology digitized and dramatically changed...

Gene Yeo describes the latest advances in RNA and discusses mRNA, RNAi, antisense, exon skipping and more.

General Partner Ross Barrett talks about how a new, larger fund will enable them to invest in more companies, and he shares some...

As a practicing clinician, Caroline Chung became increasingly focused on digital solutions. Today, she tells us how it is impacting...

Jeff Jones notes how radioisotopes are being added to more than just antibodies, and calls out upcoming data from Perspective...

He discusses pathways that could play a role in helping solve this problem, including combinations with ADCs, STING and CD47, and work by...